Navigation Links
New hope in fight against multi-resistant germs
Date:2/13/2013

This press release is available in German.

An increasing number of bacteria is evolving antibiotic resistance. Much-feared representatives of this steadily growing group include Staphylococci strains. At this point, multi-resistant forms of the bacterium Staphylococcus aureus - the "hospital germ" known commonly by its acronym, MRSA - can only be treated with a select subset of antibiotics as many drugs have simply stopped working. This is precisely why the field of medicine is in desperate need of new treatment options.

One highly promising drug candidate is now scheduled for testing in clinical trials. The substance, developed by the British pharmaceutical company GlaxoSmithKline, is still known by its rather cryptic working name, GSK1322322. In the course of clinical trials to evaluate new drugs, physicians typically end up with large numbers of patient samples that are invaluable in studying the different diseases patients are suffering from - samples that have, until recently, rarely been recruited for research purposes. Now, scientists at the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany, and at the TWINCORE Centre for Experimental and Clinical Infection Research in Hannover, Germany, aim to study such patient samples for a five-year-period. Part of a special collection at the Hannover Medical School's biobank, the samples will allow researchers to find out more about the etiology, course, and characteristic marker substances of infectious diseases. IMI, the Innovative Medicines Initiative, has awarded the scientists research grants totaling 6 million Euros as part of the COMBACTE (Combating Bacterial Resistance in Europe) project. IMI is a joint initiative by the European Union and the pharmaceutical industry. Dr. Frank Pessler, who heads TWINCORE's "Biomarkers in Infectious Diseases" research group, secured the grant and is the project's coordinator at HZI. Under his helmage, the scientists, along with their colleagues in Paris, Barcelona, and Philadelphia, will be searching for biomarkers - molecules that are unique to a particular disease and which may provide information about if the diagnosis was correct and whether or not the therapy is working.

The new antibiotic, GSK1322322, targets gram-positive bacteria including methicillin-resistant strains of Staphylococcus aureus - notorious MRSA - capable of causing serious skin and wound infections. Gram-positive germs are also frequently the culprit behind pneumonia. The drug targets the bacterial enzyme peptide deformylase. Phase I clinical trials, designed to evaluate a new drug's tolerability and safety profile, have already successfully concluded and showed only minor adverse effects. If the next study shows that GSK1322322 does not bestow any added benefit compared to current treatments, it will not be admitted into the next round of clinical trials. "This is where COMBACTE's added scientific value comes into play. In case this happens, the samples that were obtained will still offer insights into the infections they were supposed to treat, and perhaps aid in developing other better treatments" Frank Pessler explains.

Besides Pessler's own group, research teams headed by Prof. Susanne Hussler, Prof. Singh Chhatwal, Prof. Dietmar Pieper, Dr. Eva Medina, Prof. Irene Wagner-Dbler, Dr. Robert Geffers and Prof. Frank Klawonn are also involved in the project. Each team contributes its own special know-how, and, in concert, they are an excellent force. Adds Pessler: "Where else do you find this many experts from all these different disciplines under one roof, some of them even on the same floor? It makes the whole collaboration smooth and efficient."


'/>"/>

Contact: Jan Grabowski
jan.grabowski@helmholtz-hzi.de
49-531-618-11407
Helmholtz Centre for Infection Research
Source:Eurekalert  

Related medicine news :

1. WeightLossApp.com: The Skinny: Fighting Obesity in the Workplace Through an Innovative Mobile Application
2. Tiger Schulmann's MMA Student, Uriah Hall, Debuts on The Ultimate Fighter
3. Scientists Explore How Zinc Fights Off Infection
4. Electrical Brain Stimulation Plus Drug Fights Depression: Study
5. Tree-Savers™ Reports Successful Launch of Private St Beetle Lab; 100,000 Predator Beetles Now Available to Fight HWA Infestation
6. Scientists identify new strategy to fight deadly infection in cystic fibrosis
7. Bacterial supplement could help young pigs fight disease
8. Bioethics leader calls for bold approach to fighting obesity
9. Voices Against Brain Cancer Responds to a Mother’s Successful Fight Against her Glioblastoma
10. Vaccines Might Become Another Way to Fight Cancer
11. New American Chemical Society podcast: Leaves of carob tree fight food-poisoning bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New hope in fight against multi-resistant germs
(Date:7/28/2017)... ... 28, 2017 , ... The Military Family Initiative (MFI), a ... the grant recipients of its inaugural community outreach grant program. , MOAA ... Falcon’s Landing Chapter, Sterling, Va.: $5,000. Community Veterans Collaboration. , ...
(Date:7/28/2017)... ... July 28, 2017 , ... Stephen Weber, MD, is excited to ... science of Platelet Rich Plasma (PRP). Founder of Weber Facial Plastic Surgery, Dr. Weber’s ... women. Through his groundbreaking PRP procedures, Dr. Weber is quickly bringing hair loss treatment ...
(Date:7/28/2017)... , ... July 28, 2017 , ... ActivePDF, a global ... Best Places to Work in Orange County. As a multi-year recipient, ActivePDF continues to ... County, CA. , ActivePDF is known for their code-driven suite of PDF automation products, ...
(Date:7/28/2017)... ... July 28, 2017 , ... At its first ginger symposium on July 18, ... ginger industry. The funds will be used for land preparation, seed and organic farming ... budget will support both new and existing small-hold farmers and will also help strengthen ...
(Date:7/28/2017)... ... July 28, 2017 , ... Date aired: July 17th, 2017 , Guest: ... of first generation immigrants before her, Rose Hong came to America to realize a ... the part of loving parents who made sure their daughter got to the U.S. ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... Minn. , July 20, 2017  Prime Therapeutics LLC ... Jonathan Gavras , M.D., following today,s Institute for Clinical and ... report on the effectiveness and value of abuse-deterrent formulations ... on the policy roundtable at the meeting. ... not a material cost benefit to the use of abuse-deterrent ...
(Date:7/17/2017)... -- MedX Holdings, Inc., the manufacturer and global distributor of ... today announced the national roll out of its MedX ... standard for the treatment of low back injuries and ... How it works: MedX ... who prescribe the MedX Home Back Machine Program for ...
(Date:7/14/2017)... DUBLIN , July 14, 2017 Endo International plc ... results on Tuesday, August 8, 2017.  Members of its senior management ... financial markets open at 8:30 a.m. ET. The ... (866) 497-0462, International (678) 509-7598, and the passcode is 45397076. ... A replay of the ...
Breaking Medicine Technology: